# US 2024/0190936 A1 · Incretin Analogs and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0190936 A1
- Document ID: US20240190936A1
- Status: Published application
- Kind: A1
- Application number: 18/497,390
- Filed: 2023-10-30
- Published: 2024-06-13
- Earliest claimed: 2017-12-21
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Jorge Alsina-Fernandez; Tamer Coskun; Lili Guo; Hongchang Qu
- Web page: https://patentgrep.com/patent/US20240190936A1

## CPC

- C07K 14/605: Glucagons
- A61K 38/26: Glucagons
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Incretin analogs are provided that have activity at each of the GIP. GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus. dyslipidemia. fatty liver disease, metabolic syndrome, non-alcoholic steato-hepatitis and obesity.

## Claims

### Claim 1

An incretin analog comprising:
YX2X3GTX6TSDYSIX13LDKX17AQX20AFIEYLLEGGPSSGAPPPS,
wherein:
X2 is Aib,
X3 is Q or H,
X6 is aMeF or αMeF(2F),
X13 is L or aMeL,
X17 is any amino acid with a functional group available for conjugation, and the functional group is conjugated to a C16-C22 fatty acid,
X20 is Aib, Q or H,
(SEQ ID NO:5), and the C-terminal amino acid is optionally amidated;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The incretin analog of claim 1, wherein the amino acid with a functional group available for conjugation at position X17 is selected from the group consisting of K, C, E and D.

### Claim 3 (depends on 1)

The incretin analog of claim 1, wherein the amino acid with a functional group available for conjugation at position X17 is K.

### Claim 4 (depends on 1)

The incretin analog of claim 1, wherein the amino acid with the functional group available for conjugation at position X17 and the C16-C22 fatty acid are conjugated by a linker between the amino acid and the fatty acid.

### Claim 5 (depends on 4)

The incretin analog of claim 4, wherein the linker comprises one to four amino acids.

### Claim 6 (depends on 5)

The incretin analog of claim 5, wherein the amino acids are Glu or γGlu.

### Claim 7 (depends on 4)

The incretin analog of claim 4, wherein the linker further comprises the following structure:
H—{NH—CH2—CH2—[O—CH2—CH2]m—O—(CH2)p—CO}n—OH, wherein m is any integer from 1 to 12, n is any integer from 1 to 12, and p is 1 or 2.

### Claim 8 (depends on 4)

The incretin analog of claim 4, wherein the linker further comprises one to four (2-[2-(2-amino-ethoxy)-ethoxy]-acetyl) moieties.

### Claim 9 (depends on 1)

The incretin analog of claim 1, wherein X17 is K chemically modified through conjugation to an epsilon-amino group of a K side-chain with the following structure:
(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)a-(γGlu)b—CO—(CH2)c—CO2H, wherein a is 0, 1 or 2; b is 1 or 2; and c is an integer between 16 to 18.

### Claim 10 (depends on 9)

The incretin analog of claim 9, wherein a is 1.

### Claim 11 (depends on 9)

The incretin analog of claim 9, wherein a is 2.

### Claim 12 (depends on 9)

The incretin analog of claim 9, wherein b is 1.

### Claim 13 (depends on 9)

The incretin analog of claim 9, wherein b is 2.

### Claim 14 (depends on 9)

The incretin analog of claim 9, wherein c is 18.

### Claim 15 (depends on 1)

The incretin analog of claim 1, wherein X13 is αMeL.

### Claim 16 (depends on 1)

The incretin analog of claim 1, wherein X13 is L.

### Claim 17 (depends on 1)

The incretin analog of claim 1, wherein X3 is Q.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The incretin analog of claim 1, wherein X6 is αMeF.

### Claim 20 (depends on 1)

The incretin analog of claim 1, wherein X6 is αMeF(2F).

### Claim 21

An incretin analog having a formula selected from the group consisting of SEQ ID NOS: 5-7 and 9-11.

### Claim 22 (depends on 1)

A method of treating a disease selected from the group consisting of diabetes mellitus, obesity, fatty liver disease, non-alcoholic steatohepatitis, dyslipidemia and metabolic syndrome, the method comprising the step of:
administering to an individual in need thereof an effective amount of an incretin analog of claim 1.

### Claim 23 (depends on 1)

A method of treating type II diabetes mellitus, the method comprising the step of:
administering to an individual in need thereof an effective amount of an incretin analog of claim 1.

### Claim 24 (depends on 1)

A pharmaceutical composition comprising:
an incretin analog of claim 1; and
a pharmaceutically acceptable carrier, diluent, or excipient.

### Claim at position 25

25-28. (canceled)
